CTOs on the Move

XyloCor

www.xylocor.com

 
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Alexander Gaidamaka
Senior Vice President of Technology, Manufacturing and Quality Profile

Funding

XyloCor raised $17M on 12/06/2018
XyloCor raised $22.6M on 03/22/2021

Similar Companies

northcoast medical

northcoast medical is a Morgan Hill, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sage Rutty and Co

Sage Rutty and Co is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Progenika

Progenika is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunai

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes

Horizon Discovery

Horizon builds human disease models and reagents derived from genetically-engineered cells that its customers use, or that are deployed on their behalf to: gain knowledge of the genetic drivers of disease; develop novel drugs or cell therapies targeted...